3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Conditions
Carcinoma, Non-Small-Cell Lung
57
Breast Neoplasms
34
Neoplasms
31
Parkinson Disease 4, Autosomal Dominant Lewy Body
26
Multiple Myeloma
20
Recurrence
19
Leukemia, Myeloid, Acute
19
Neoplasm Metastasis
17
Colorectal Neoplasms
16
Lymphoma, Non-Hodgkin
15
Melanoma
13
Leukemia, Lymphocytic, Chronic, B-Cell
13
Leukemia
13
Carcinoma, Renal Cell
13
Ovarian Neoplasms
12
Lymphoma, Follicular
12
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Myelodysplastic Syndromes
11
Urinary Bladder Neoplasms
10
Lung Neoplasms
10
Lymphoma, Mantle-Cell
9
Lymphoma, Large B-Cell, Diffuse
9
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
9
Hematologic Neoplasms
9
Carcinoma, Hepatocellular
9
Adenocarcinoma
9
Stomach Neoplasms
8
Small Cell Lung Carcinoma
8
Prostatic Neoplasms
8
Lymphoma, B-Cell, Marginal Zone
8
Interventions
enfortumab vedotin
2
pembrolizumab
1
avelumab
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
INDUSTRY
×
Has announcements
×
Urologic Neoplasms
×
Clear all
NCT03288545
2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2
Terminated
348 enrolled
1 FDA
NCT03219333
2024-08-27
EV-201
Astellas Pharma Inc
Phase 2
Completed
219 enrolled
32 charts
2 FDA
NCT02603432
2024-03-27
JAVELIN Bladder 100
Pfizer
Phase 3
Completed
700 enrolled
35 charts
1 FDA